Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing, including time to enroll clinical studies; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013, the quarterly reports on Form 10-Q filed on May 14, 2013 and August 19, 2013, and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Cell therapy using patients own bone marrow may present option for heart disease
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Entomology 2012 to present 105 insect symposia in November
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. The Brain Prize 2012 is presented May 9th
6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. Coral reef experts to present latest coral reef science during July symposium
10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... pharmaceutical industry is struggling to deal with bacteria that ... is the similar struggle in agribusiness to deal with ... is widely used in farming practice. The herbicide, ... in Monsanto,s Roundup products and also in herbicides produced ...
... Mich. Sheng Yang He, plant biologist at Michigan ... most-innovative plant scientists as part of a $75 million ... Medical Institute and the Gordon and Betty Moore Foundation ... Laboratory, and 14 other researchers from around the country. ...
... HOUSTON (June 16, 2011) Researchers at The ... have been awarded nearly $1 million to investigate Adenovirus-36 ... The grant is being awarded by the Federal Emergency ... The study will examine the relationship of Ad-36 to ...
Cached Biology News:Scientists learn how horseweed shrugs off herbicide 2Scientists learn how horseweed shrugs off herbicide 3Scientists learn how horseweed shrugs off herbicide 4Scientists learn how horseweed shrugs off herbicide 5MSU plant scientist named one of the nation's most innovative researchers 2UTHealth awarded FEMA grant to explore novel obesity risk factor among firefighters 2UTHealth awarded FEMA grant to explore novel obesity risk factor among firefighters 3
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 /PRNewswire/ ... today announced the intent of the National Institute of Allergy ... of Health (NIH) within the Department of Health and Human ... be held in the United States ... of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... D Garteiz, TexMS Analytical Services, Houston, TX , ... A Varian 1200L LC/MS/MS system was used for ... therapeutic agents to the urinary tract using a urethra suppository mode of ... tract disease is a major health problem in the U.S. and will ...
... , ... Oxidative stress, radiation and other external insults ... diverse as bacteria, yeast, drosophila, rodents and man (Friedberg et al. ... to allow time for DNA repair processes to occur. If however, the system ...
... Ryan Varian Australia Pty. Ltd., Mulgrave, 3170, Victoria, Australia , ... The role of major, minor and trace levels of ... In particular, research on the value of trace elements to the diagnosis, ... The advent of atomic absorption (AA) techniques and the ...
Cached Biology Technology:Quantitation of Oxybutynin in Rabbit Plasma Using the Varian 1200L LC/MS/MS System 2Quantitation of Oxybutynin in Rabbit Plasma Using the Varian 1200L LC/MS/MS System 3DNA Damage and Repair - Quantification of Sub-Cellular Events Using Automated Confocal Imaging 2DNA Damage and Repair - Quantification of Sub-Cellular Events Using Automated Confocal Imaging 3DNA Damage and Repair - Quantification of Sub-Cellular Events Using Automated Confocal Imaging 4DNA Damage and Repair - Quantification of Sub-Cellular Events Using Automated Confocal Imaging 5Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 2Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 3Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 4Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 5Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 6Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 7Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 8Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 9Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 10Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 11Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 12
Laminin beta-2 (C4)...
Anti-MD-2 (IN) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
VMAT 2 (N-19)...
Calcium Channel alpha 2 delta-2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone 42, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: